Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
ACS Omega
2023 Oct 31;843:40890-40897. doi: 10.1021/acsomega.3c06111.
Show Gene links
Show Anatomy links
Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated from Nectandra leucantha-A Preclinical Study against Schistosoma mansoni Infection.
Rocha VC
,
Cajas RA
,
Andrade-de-Siqueira AI
,
Almeida RBP
,
Godoy-Silva J
,
Gonçalves MM
,
Lago JHG
,
de Moraes J
.
Abstract
Schistosomiasis, a parasitic disease affecting nearly 250 million individuals globally, poses a significant health challenge. With praziquantel being the sole available treatment and its limited efficacy in early stage infections, the identification of novel bioactive compounds becomes imperative. This study examines the potential of dehydrodieugenol B (1) and its methyl ether (2), derived from the leaves of the Brazilian Nectandra leucantha plant (Lauraceae), in combatting Schistosoma mansoni infections through a preclinical approach. Initially, compound 1 displayed noteworthy in vitro antiparasitic activity with an EC50 of 31.9 μM, showcasing low toxicity in mammalian cells and an in vivo animal model (Caenorhabditis elegans). Conversely, compound 2 exhibited no activity. In silico predictions pointed to favorable oral bioavailability and the absence of PAINS similarities. Subsequently, a single oral dose of 400 mg/kg of compound 1 or praziquantel was administered to mice infected with adult (patent infection) or immature parasites (prepatent infection). Remarkably, in prepatent infections, 1 resulted in a significant reduction (approximately 50%) in both worm and egg burden, while praziquantel reduced worm and egg numbers by 30%. The superior efficacy of dehydrodieugenol B (1) compared to praziquantel in premature infections holds the potential to advance the development of new molecular prototypes for schistosomiasis treatment.
Amorim,
Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies.
2020, Pubmed
Amorim,
Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies.
2020,
Pubmed
Brito,
Neolignans isolated from Saururus cernuus L. (Saururaceae) exhibit efficacy against Schistosoma mansoni.
2022,
Pubmed
,
Echinobase
Caldwell,
Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022.
2023,
Pubmed
Costa,
The other side of tropical forest drought: do shallow water table regions of Amazonia act as large-scale hydrological refugia from drought?
2023,
Pubmed
Ferreira,
Approaches to advance drug discovery for neglected tropical diseases.
2022,
Pubmed
Galhardo,
New derivatives from dehydrodieugenol B and its methyl ether displayed high anti-Trypanosoma cruzi activity and cause depolarization of the plasma membrane and collapse the mitochondrial membrane potential.
2022,
Pubmed
,
Echinobase
Grecco,
Neolignans isolated from twigs of Nectandra leucantha Ness & Mart (Lauraceae) displayed in vitro antileishmanial activity.
2018,
Pubmed
,
Echinobase
Grecco,
Neolignans from leaves of Nectandra leucantha (Lauraceae) display in vitro antitrypanosomal activity via plasma membrane and mitochondrial damages.
2017,
Pubmed
,
Echinobase
Guerra,
In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing.
2019,
Pubmed
Kabuyaya,
Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review.
2018,
Pubmed
Lago,
Antischistosomal agents: state of art and perspectives.
2018,
Pubmed
Lago,
Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis.
2019,
Pubmed
McManus,
Schistosomiasis.
2018,
Pubmed
Mengarda,
Recent approaches in nanocarrier-based therapies for neglected tropical diseases.
2023,
Pubmed
Mengarda,
Licarin A, a neolignan isolated from Nectandra oppositifolia Nees & Mart. (Lauraceae), exhibited moderate preclinical efficacy against Schistosoma mansoni infection.
2021,
Pubmed
Mengarda,
Recent trends in praziquantel nanoformulations for helminthiasis treatment.
2022,
Pubmed
Mengarda,
Antiparasitic activity of piplartine (piperlongumine) in a mouse model of schistosomiasis.
2020,
Pubmed
Mugumbate,
The relationship between target-class and the physicochemical properties of antibacterial drugs.
2015,
Pubmed
Rando,
Vanillin-Related N-Acylhydrazones: Synthesis, Antischistosomal Properties and Target Fishing Studies.
2019,
Pubmed
,
Echinobase
Roquini,
Susceptibility of Angiostrongylus cantonensis Larvae to Anthelmintic Drugs.
2022,
Pubmed
Roquini,
Promethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepato-, and splenomegaly in a schistosomiasis animal model.
2019,
Pubmed
Roquini,
The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro, In Vivo, and In Silico Studies of Macromolecular Targets.
2023,
Pubmed
,
Echinobase
Sear,
Synthesis and Structure-Activity Relationship of Dehydrodieugenol B Neolignans against Trypanosoma cruzi.
2020,
Pubmed
Sessa,
15β-Senecioyl-oxy-ent-kaur-16-en-19-oic Acid, a Diterpene Isolated from Baccharis lateralis, as Promising Oral Compound for the Treatment of Schistosomiasis.
2020,
Pubmed
Silva,
New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies.
2021,
Pubmed
Silva,
Brazilian red propolis exhibits antiparasitic properties in vitro and reduces worm burden and egg production in an mouse model harboring either early or chronic Schistosoma mansoni infection.
2021,
Pubmed
Spangenberg,
Alternatives to Praziquantel for the Prevention and Control of Schistosomiasis.
2021,
Pubmed
Stiernagle,
Maintenance of C. elegans.
2006,
Pubmed
Wang,
Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications.
2022,
Pubmed
Xavier,
H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies.
2020,
Pubmed
da Costa-Silva,
Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from Nectandra leucantha.
2015,
Pubmed
de Brito,
Cyclohexene-fused 1,3-oxazines with selective antibacterial and antiparasitic action and low cytotoxic effects.
2017,
Pubmed
de Moraes,
FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?
2020,
Pubmed
